Get the Stockscreener App
8.42
5.61%
-0.50
After Hours:
8.76
0.34
+4.04%
Promis Neurosciences Inc stock is traded at $8.42, with a volume of 48,254.
It is down -5.61% in the last 24 hours and down -7.24% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.
See More
Previous Close:
$8.92
Open:
$9.13
24h Volume:
48,254
Relative Volume:
1.57
Market Cap:
$18.12M
Revenue:
-
Net Income/Loss:
$-563.30K
P/E Ratio:
-42.18
EPS:
-0.1996
Net Cash Flow:
$-22.23M
1W Performance:
-3.83%
1M Performance:
-7.24%
6M Performance:
-32.64%
1Y Performance:
-61.86%
1-Day Range:
$8.31
$9.15
1-Week Range:
$8.31
$9.42
52-Week Range:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
8.42 | 19.20M | 0 | -563.30K | -22.23M | -0.1996 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.38 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.71 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
396.04 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
847.05 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
166.55 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Promis Neurosciences Inc Stock (PMN) Latest News
ProMIS Neurosciences completes enrollment for Alzheimer’s drug trial By Investing.com - Investing.com Nigeria
ProMIS Neurosciences (PMN) Completes Patient Enrollment for Alzh - GuruFocus
ProMIS Neurosciences completes enrollment for Alzheimer’s drug trial - Investing.com India
ProMIS Neurosciences exceeds target enrollment in Precise-AD phase 1b clinical trial - marketscreener.com
ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 ... - Caledonian Record
Alzheimer's study of new antibody fully enrolled, no treatment SAEs so far - Stock Titan
Why ProMIS Neurosciences Inc. (23J0) stock could outperform next year2025 Market Overview & Expert Curated Trade Setups - Улправда
ProMIS Neurosciences regains Nasdaq compliance with minimum bid price rule - Investing.com Nigeria
ProMIS Neurosciences Regains Nasdaq Compliance - TipRanks
ProMIS Neurosciences Announces Third Quarter 2019 Results - PR Newswire
ProMIS Neurosciences shareholders approve share consolidation proposal By Investing.com - Investing.com Nigeria
ProMIS Neurosciences regains Nasdaq compliance - MSN
ProMIS Neurosciences shareholders approve share consolidation proposal - Investing.com
ProMIS Neurosciences (PMN) Reveals Promising Study Results for A - GuruFocus
ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk - marketscreener.com
Pretax income of ProMIS Neurosciences Inc. – BER:23J - TradingView
ProMIS Neurosciences (PMN) Price Target Increased by 2,288.89% to 137.06 - Nasdaq
Can ProMIS Neurosciences Inc. (23J0) stock sustain margin levelsJuly 2025 Closing Moves & Weekly Top Gainers Alerts - Newser
HC Wainwright Has Strong Forecast for PMN FY2025 Earnings - Defense World
How strong is ProMIS Neurosciences Inc. (23J0) stock earnings growth2025 Institutional Moves & Weekly Breakout Watchlists - Newser
How geopolitical risks impact ProMIS Neurosciences Inc. (23J0) stock2025 Market Trends & Long-Term Growth Stock Strategies - Newser
ProMIS Neurosciences announces publication on plasma pTau in Alzheimer’s - MSN
ProMIS Neurosciences target adjusted to $18 from $4 at H.C. Wainwright - MSN
ProMIS Neurosciences Shares Advance After New Data Supports Alzheimer’s Trial Strategy - MSN
Why hedge funds are buying ProMIS Neurosciences Inc. stockWeekly Trade Recap & AI Based Buy/Sell Signal Reports - Newser
symbol__ Stock Quote Price and Forecast - CNN
HC Wainwright & Co. Maintains ProMIS Neurosciences (PMN) Buy Recommendation - Nasdaq
ProMIS Neurosciences Inc (23J0.DU) Valuation Measures & Financial Statistics - Yahoo! Finance Canada
PMN: HC Wainwright & Co. Raises Price Target and Maintains Buy R - GuruFocus
ProMIS Neurosciences stock rises after promising Alzheimer’s research data By Investing.com - Investing.com Nigeria
ProMIS Neurosciences (PMN) Sees Revised Price Target from H.C. W - GuruFocus
ProMIS Neurosciences stock rises after promising Alzheimer’s research data - Investing.com
ProMIS Neurosciences (PMN) Presents Key Insights in Alzheimer's Research - GuruFocus
Plasma pTau identified as key early endpoint in Alzheimer's research - marketscreener.com
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310 - Sahm
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference - marketscreener.com
ProMIS Neurosciences Inc. Financial Statements – TRADEGATE:23J - TradingView
EBITDA of ProMIS Neurosciences Inc. – TRADEGATE:23J - TradingView
ProMIS Neurosciences Inc. Financial Disclosures & Filings - TradingView
Diluted net income available to common stockholders of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Net margin % of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Net income before discontinued operations of ProMIS Neurosciences Inc. – FWB:23J - TradingView
Total common shares outstanding of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Enterprise value of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Promis Neurosciences (NASDAQ:PMN) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
Price to cash flow ratio of PROMIS NEUROSCIENCES – FWB:23J - TradingView
Tangible book value per share of PROMIS NEUROSCIENCES – FWB:23J - TradingView
ProMIS Neurosciences (STU:23J) Beneish M-Score : 0.00 (As of Nov. 30, 2025) - GuruFocus
ProMIS Neurosciences (STU:23J) Gross Margin % : 0.00% (As of Sep. 2025) - GuruFocus
ProMIS Neurosciences (STU:23J) Other Financing : €0.00 Mil (TTM As of Sep. 2025) - GuruFocus
ProMIS Neurosciences Inc (STU:23J) Stock Price & 30 Year Financial Data - GuruFocus
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.31%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):